68Ga-JH04 PET/CT in Patients With Various Types of Cancer
Launched by FIRST AFFILIATED HOSPITAL OF FUJIAN MEDICAL UNIVERSITY · Jun 7, 2024
Trial Information
Current as of August 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new imaging agent called 68Ga-JH04, which may help doctors see various types of cancer more clearly using a special type of scan called PET/CT. The researchers want to find out how well 68Ga-JH04 works compared to other imaging agents that are already used in cancer diagnosis. They are looking for patients with different solid tumors who can provide tissue samples (histopathological findings) and are between the ages of 65 and 74 or 29 and 219. Participants must also be able to give their consent to join the study and cannot be pregnant, breastfeeding, or have severe liver or kidney problems.
If you participate in this trial, you can expect to undergo imaging scans to help assess how well the new agent works. This study is currently recruiting participants, and your involvement could contribute to improving cancer imaging techniques for future patients. It’s a chance to help advance cancer research while receiving thorough monitoring and care during the trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Various solid tumors with available histopathological findings Signed informed consent
- Exclusion Criteria:
- • pregnant or lactational women who suffered from severe hepatic and renal insufficiency
About First Affiliated Hospital Of Fujian Medical University
The First Affiliated Hospital of Fujian Medical University is a leading medical institution dedicated to advancing healthcare through innovative clinical research and education. As a premier sponsor of clinical trials, the hospital is committed to improving patient outcomes and contributing to medical knowledge across various specialties. With a robust infrastructure and a multidisciplinary team of experienced researchers and healthcare professionals, the hospital ensures the ethical conduct and scientific rigor of its trials, fostering collaboration with global research communities. Its mission is to enhance the quality of care through evidence-based practices and to support the development of novel therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fuzhou, , China
Fuzhou, Fujian, China
Patients applied
Trial Officials
Weibing Miao, MD
Principal Investigator
The First Affiliated Hospital, Fujian Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported